This session explores current advances in the diagnosis and treatment of obesity and its metabolic complications. Experts discuss the shift toward complication-centric models of obesity care and highlight the expanding role of incretin-based therapies, from GLP-1 mono-agonists to emerging dual and triple agonists. Obesity-related MASLD is examined with a focus on modern pathways for risk stratification and non-invasive assessment of liver fibrosis, while nutritional challenges arising with incretin-induced weight loss are addressed through practical guidance on protein intake, micronutrient monitoring, and strategies to preserve muscle mass. Together, the session provides an integrated perspective on how modern pharmacotherapy, liver-focused evaluation, and tailored nutrition can improve outcomes for people with obesity.